🚨 ESMO 2026 | FLAURA2 ctDNA Analysis
🔬 Early EGFRm clearance was prognostic, NOT predictive of PFS/OS benefit.
✅ Osimertinib + chemotherapy improved outcomes regardless of early ctDNA clearance.
💡 Early ctDNA clearance cannot justify chemotherapy omission.
#ESMO26
16 views · 1 like · 1 repost · 0 replies
FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem)
https://esmocongress.esmo.orgPACE-LUNG: A multicenter, single-arm, phase II clinical trial evaluating the efficacy of additional chemotherapy for patients with EGFRm NSCLC with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line
https://esmocongress.esmo.orgSource: OsmanKostekMD · x.com